Business
Dermata to Present on BioPub on January 31, 2025
- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -SAN DIEGO, CA / ACCESS Newswire / January 29, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) (\"Dermata\" or the \"Company\"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be featured as the presenting company on BioPub on January 31, 2025, at 12:00PM ET. This live, interactive, online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Gerry Proehl, and Chief Development Officer, Chris Nardo, Ph.D., in real time. Mr. Proehl and Dr. Nardo will provide an update of the Company's progress on their ongoing XYNGARI™ STAR-1 Phase 3 clinical trial, which has topline results expected in March 2025, discuss the recent collaboration agreement signed with Revance Therapeutics, and answer audience questions.Event: BioPub Presents DermataDate: January 31, 2025Time: 12:00PM Eastern TimeLocation: VirtualTo attend the presentation, please use the following Link on the day of the event or contact Cliff Mastricola at [email protected] for more information.If you are not able to join the event live on the day of the presentation, an archived webcast will also be made available on BioPub and Torrey Hills Capital. Interested investors may reach out to the Company using the contact information below.About Dermata TherapeuticsDermata Therapeutics is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. Dermata's lead product candidate, XYNGARI™ (formerly DMT310), is its first product candidate being developed from its Spongilla technology platform. XYNGARI™ is a once-weekly, topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. In addition to acne, XYNGARI™ has been studied for the treatment of psoriasis and rosacea. Dermata's second program, uses XYNGARI™ as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin diseases and conditions. Dermata is headquartered in San Diego, California. For more information, plea...